NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing intranasal and intramuscular vaccines, based on its patented NanoStat™ technology platform. Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio’s lead product candidates include vaccines for RSV, seasonal and pandemic influenza, pertussis, anthrax and HSV2. The platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease

Research Grants show all

NIH5

Patents show all

32Applications9Issued

Clinical Trials show all

3Phase 32Phase 12Phase 2

SEC Filings show all

D4

Contact Information

2311 Green Road, Suite A
Ann Arbor, MI 48105
United States

17343029150

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $82,800,00011-502017-03-06Operating

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2006-10-21$30,000,000VenturePerseus
    2016-02-04$1,800,000Convertible_note
    2010-11-30$6,000,000GrantBill & Melinda Gates Foundation
    2009-02-18$12,000,000VenturePerseus
    2017-03-06GrantSBIR
    2012-11-28$11,000,000VentureVenture Investors, Perseus
    2009-07-08$22,000,000VentureVenture InvestorsPerseus

    SEC Form D Funding Events

    DateOfferedSoldType
    2009-05-29Indefinite$10,000,000Other
    2008-12-11UnknownUnknownOther (Paper Filing)

    Key Executives

    • James R. Baker, Jr.
      Executive Officer
    • David Peralta
      Executive Officer
    • Norman C. Selby
      Director
    • Ronald M. Cresswell
      Director
    • Daniel B. Dubin
      Director
    • Robert C. Moellering
      Director
    • David M. Stout
      Director